Early access
Sign in
Taking people in FrancePhase 2/3

Brain scans of inflammation in people with schizophrenia and healthy volunteers

Uses PET brain scans to study inflammation in people with schizophrenia.

Key facts

Who runs it
Institut National De La Sante Et De La Recherche Medicale
Where
Creteil and ORSAY, FranceSee the 2 sites
Registry title
Assessment of microglial activation in patients with schizophrenia stratified for C4 complement by PET using [18F]DPA-714
Status
Recruiting
Phase
Phase 2/3
People taking part
75 people, planned
Started
17 Nov 2025
Expected to end
30 May 2028
Type of study
Interventional
Record updated
16 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with schizophrenia and healthy volunteers of similar age and sex. It studies brain inflammation on a PET scan in relation to a genetic marker (C4/HLA).

Age
18 to 55 years (the record also lists a maximum age of 64 years).
Sex
Men and women can join.
Disease stage
Schizophrenia diagnosed by DSM-5 criteria, or healthy controls with no history of a major psychiatric illness.
Earlier treatment
No scan with ionizing radiation (PET, SPECT or nuclear medicine) in the year before or during another study's exclusion period.
Biomarker or test result
Patients and controls are grouped by the HLA 8.1 AH haplotype (present or absent). A TSPO genotype that allows tracer binding is required.

Main reasons for not taking part

  • Ongoing chronic inflammatory disease (rheumatic, digestive or autoimmune)
  • Known allergy to the radiopharmaceutical [18F]DPA-714 or its excipients
  • History of severe kidney or liver failure
  • Contraindication to MRI or claustrophobia
  • Current pregnancy or breastfeeding

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Male or Female, aged from 18 to 55, patients with schizophrenia diagnostic according to DSM-5 and presenting HLA 8.1 AH haplotype (8.1 AH+) or presenting no HLA 8.1 AH haplotype ( (8.1 AH-)
  • Male or Female healthy controls aged from 18 to 55 matched regarding age, sex, HLA/C4 according to patients (8.1 AH+ or 8.1 AH-)
  • Having Efficient Contraception for women of reproductive age ( contraception will be considered effective from the moment the patient declares the use of an oral contraceptive, the presence of an IUD other than copper ones, a diaphragm or a contraceptive implant, or the completion of a tubal ligation or sterilization by Essure process)
  • Be able to understand research objectives and procedures
  • Be affiliated with or be a beneficiary of a social security scheme
  • Genetic criterion: TSPO genotype allowing tracer fixation (90% of subjects)
  • Have signed a free and informed consent

Who cannot take part

  • Participation in research or management of a pathology with ionizing radiation exposure as part of a nuclear medicine examination (PET, SPECT, NM) in the year prior to or during the exclusion period of another research
  • Progressive chronic inflammatory disease (rheumatic, digestive, autoimmune)
  • For healthy volunteers only : Pathology or history of Axis 1 psychiatric pathology investigated by the validated French version of the MINI (Mini International Neuropsychiatric Interview) questionnaire
  • Known hypersensitivity to radiopharmaceutical ([18F]DPA-714 or one of the excipients)
  • History of severe renal or liver failure
  • Contraindication to MRI : pacemaker or neurosensory pacemaker or implantable defibrillator; clip on an aneurysm or clip on a vascular malformation of the brain; ferromagnetic intraocular or cerebral foreign body; prosthesis or ferro-metallic objects or fragments mobilizable magnetic; cochlear implants; peripheral stimulator; ventriculoperitoneal neurosurgical bypass valves; permanent eye or lip makeup. Automatic injection device type insulin pump, blood glucose sensor
  • Adult subject to legal protection (guardianship of a tutor, or safeguard of justice)
  • Claustrophobia
  • Current pregnancy, breastfeeding
  • Person refusing to be informed of a significant health finding discovered in the research
  • Person deprived of liberty by administrative or judicial decision

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

Where in France

  • Assistance Publique Hopitaux De ParisCreteil, FranceTaking people
  • French Alternative Energies And Atomic Energy CommisionORSAY, FranceTaking people

About the trial

What the trial wants to find out

To assess the correlation between cortical neuro-inflammation quantified by Positrons Emission Tomography (PET) using [18F]DPA-714, and genetic determinants of C4 expression in patients with schizophrenia and healthy volunteers.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Assessment of microglial activation in patients with schizophrenia stratified for C4 complement by PET using [18F]DPA-714
Plain-language title
Brain scans of inflammation in people with schizophrenia and healthy volunteersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Fit questions
Built from 2023-504181-38-00, who can take part
Record updated
16 March 2026